Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck × Sorafenib × 1 year × Clear all

NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Phase 2 Completed

55 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00494182 2025-12-17

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck